Irwin Walker1, Tony Panzarella2, Stephen Couban3, Felix Couture4, Gerald Devins5, Mohamed Elemary6, Geneviève Gallagher7, Holly Kerr8, John Kuruvilla9, Stephanie J Lee10, John Moore11, Thomas Nevill12, Gizelle Popradi13, Jean Roy14, Kirk R Schultz15, David Szwajcer16, Cynthia Toze12, Ronan Foley17. 1. McMaster University and Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada. Electronic address: walkeri@mcmaster.ca. 2. Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada. 3. Dalhousie University and Capital District Health Authority Halifax, NS, Canada. 4. Centre Hospitalier Universitaire de Québec, Pavillon Hôtel-dieu de Québec, Québec City, QC, Canada. 5. University of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada. 6. Saskatoon Cancer Centre, Saskatoon, SK, Canada. 7. Université Laval, and CHA Hôpital l'Enfant-Jésus, Québec, Québec City, QC, Canada. 8. Vancouver General Hospital, Vancouver, BC, Canada. 9. University of Toronto and Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. 10. University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 11. St Vincent's Hospital, Sydney, NSW, Australia. 12. Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, British Columbia Cancer Agency, and University of British Columbia, BC, Canada. 13. Royal Victoria Hospital, Montreal, QC, Canada. 14. Université de Montréal and Maisonneuve-Rosemont Hospital, Montreal, QC, Canada. 15. Michael Cuccione Childhood Cancer Research Program and British Columbia Children's Hospital and Child & Family Research Institute, Vancouver, BC, Canada. 16. CancerCare Manitoba, Winnipeg, MB, Canada. 17. Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada.
Abstract
BACKGROUND: Pretreatment with anti-thymocyte globulin (ATG) decreases the occurrence of chronic graft-versus-host disease (CGVHD) after haemopoietic cell transplantation from an unrelated donor, but evidence of patient benefit is absent. We did a study to test whether ATG provides patient benefit, particularly in reducing the need for long-term immunosuppressive treatment after transplantation. METHODS: We did a phase 3, multicentre, open-label, randomised controlled trial at ten transplant centres in Canada and one in Australia. Eligible patients were aged 16 to 70 years with any haematological malignancy and a Karnofsky score of at least 60 receiving either myeloablative or non-myeloablative (or reduced intensity) conditioning preparative regimens before haemopoietic cell transplantation from an unrelated donor. We allocated patients first by simple randomisation (1:1), then by a minimisation method, to either pretransplantation rabbit ATG plus standard GVHD prophylaxis (ATG group) or standard GVHD prophylaxis alone (no ATG group). We gave a total dose of ATG of 4·5 mg/kg intravenously over 3 days (0·5 mg/kg 2 days before transplantation, 2·0 mg/kg 1 day before, and 2·0 mg/kg 1 day after). The primary endpoint was freedom from all systemic immunosuppressive drugs without resumption up to 12 months after transplantation. Analysis was based on a modified intention-to-treat method. This trial was registered at ISRCTN, number 29899028. FINDINGS:Between June 9, 2010, and July 8, 2013, we recruited and assigned 203 eligible patients to treatment (101 to ATG and 102 to no ATG). 37 (37%) of 99 patients who received ATG were free from immunosuppressive treatment at 12 months compared with 16 (16%) of 97 who received no ATG (adjusted odds ratio 4·25 [95% CI 1·87-9·67]; p=0·00060. The occurrence of serious adverse events (Common Terminology Criteria grades 4 or 5) did not differ between the treatment groups (34 [34%] of 99 patients in the ATG group vs 41 [42%] of 97 in the no ATG group). Epstein-Barr virus reactivation was substantially more common in patients who received ATG (20 [one of whom died-the only death due to an adverse event]) versus those who did not receive ATG (two [no deaths]). No deaths were attributable to ATG. INTERPRETATION:ATG should be added to myeloblative and non-myeloblative preparative regimens for haemopoietic cell transplantation when using unrelated donors. The benefits of decreases in steroid use are clinically significant. Epstein-Barr virus reactivation is increased, but is manageable by prospective monitoring and the use of rituximab. Future trials could determine whether the doses of ATG used in this trial are optimum, and could also provide additional evidence of a low relapse rate after non-myeloablative regimens. FUNDING: The Canadian Institutes of Health Research and Sanofi.
RCT Entities:
BACKGROUND: Pretreatment with anti-thymocyte globulin (ATG) decreases the occurrence of chronic graft-versus-host disease (CGVHD) after haemopoietic cell transplantation from an unrelated donor, but evidence of patient benefit is absent. We did a study to test whether ATG provides patient benefit, particularly in reducing the need for long-term immunosuppressive treatment after transplantation. METHODS: We did a phase 3, multicentre, open-label, randomised controlled trial at ten transplant centres in Canada and one in Australia. Eligible patients were aged 16 to 70 years with any haematological malignancy and a Karnofsky score of at least 60 receiving either myeloablative or non-myeloablative (or reduced intensity) conditioning preparative regimens before haemopoietic cell transplantation from an unrelated donor. We allocated patients first by simple randomisation (1:1), then by a minimisation method, to either pretransplantation rabbit ATG plus standard GVHD prophylaxis (ATG group) or standard GVHD prophylaxis alone (no ATG group). We gave a total dose of ATG of 4·5 mg/kg intravenously over 3 days (0·5 mg/kg 2 days before transplantation, 2·0 mg/kg 1 day before, and 2·0 mg/kg 1 day after). The primary endpoint was freedom from all systemic immunosuppressive drugs without resumption up to 12 months after transplantation. Analysis was based on a modified intention-to-treat method. This trial was registered at ISRCTN, number 29899028. FINDINGS: Between June 9, 2010, and July 8, 2013, we recruited and assigned 203 eligible patients to treatment (101 to ATG and 102 to no ATG). 37 (37%) of 99 patients who received ATG were free from immunosuppressive treatment at 12 months compared with 16 (16%) of 97 who received no ATG (adjusted odds ratio 4·25 [95% CI 1·87-9·67]; p=0·00060. The occurrence of serious adverse events (Common Terminology Criteria grades 4 or 5) did not differ between the treatment groups (34 [34%] of 99 patients in the ATG group vs 41 [42%] of 97 in the no ATG group). Epstein-Barr virus reactivation was substantially more common in patients who received ATG (20 [one of whom died-the only death due to an adverse event]) versus those who did not receive ATG (two [no deaths]). No deaths were attributable to ATG. INTERPRETATION: ATG should be added to myeloblative and non-myeloblative preparative regimens for haemopoietic cell transplantation when using unrelated donors. The benefits of decreases in steroid use are clinically significant. Epstein-Barr virus reactivation is increased, but is manageable by prospective monitoring and the use of rituximab. Future trials could determine whether the doses of ATG used in this trial are optimum, and could also provide additional evidence of a low relapse rate after non-myeloablative regimens. FUNDING: The Canadian Institutes of Health Research and Sanofi.
Authors: K Kawamura; J Kanda; S Fuji; M Murata; K Ikegame; K Yoshioka; T Fukuda; Y Ozawa; N Uchida; K Iwato; T Sakura; M Hidaka; H Hashimoto; T Ichinohe; Y Atsuta; Y Kanda Journal: Bone Marrow Transplant Date: 2017-07-17 Impact factor: 5.483
Authors: Christopher G Kanakry; Javier Bolaños-Meade; Yvette L Kasamon; Marianna Zahurak; Nadira Durakovic; Terry Furlong; Marco Mielcarek; Marta Medeot; Ivana Gojo; B Douglas Smith; Jennifer A Kanakry; Ivan M Borrello; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; William H Matsui; Lode J Swinnen; Kenneth R Cooke; Richard F Ambinder; Ephraim J Fuchs; Marcos J de Lima; Borje S Andersson; Ravi Varadhan; Paul V O'Donnell; Richard J Jones; Leo Luznik Journal: Blood Date: 2017-01-03 Impact factor: 22.113
Authors: Pere Barba; Rodrigo Martino; Qin Zhou; Christina Cho; Hugo Castro-Malaspina; Sean Devlin; Albert Esquirol; Sergio Giralt; Ann A Jakubowski; Dolores Caballero; Molly Maloy; Esperanza B Papadopoulos; José Luís Piñana; María Laura Fox; Francisco J Márquez-Malaver; David Valcárcel; Carlos Solano; Lucía López-Corral; Jorge Sierra; Miguel-Angel Perales Journal: Biol Blood Marrow Transplant Date: 2018-01-02 Impact factor: 5.742
Authors: Rosy Dabas; Kareem Jamani; Shahbal B Kangarloo; Poonam Dharmani-Khan; Tyler S Williamson; Samar Ousia; Caylib Durand; Don Morris; Douglas Mahoney; Lynn Savoie; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Faisal M Khan; Andrew Daly; Jan Storek Journal: Blood Adv Date: 2019-05-14
Authors: Michael Scordo; Valkal Bhatt; Patrick Hilden; Melody Smith; Katie Thoren; Christina Cho; Gunjan L Shah; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Scott T Avecilla; Richard J O'Reilly; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Jaap J Boelens; Miguel-Angel Perales; Sergio A Giralt Journal: Biol Blood Marrow Transplant Date: 2019-03-01 Impact factor: 5.742